


AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A compound according to Formula I, wherein



Formula I

X is O, NOH, NO(1-4C)alkyl, NO(1-4C)acyl;

A1-A5 are C, substituted with R1, or N, provided that at least one and not more than three of A1-A5 are N; or

one or two of A1, A2 and A5 are N, and the others are C, substituted with R1, and A3 and A4 together represent a fused benzo ring or a fused five- or six-membered nitrogen-containing aromatic ring, both optionally substituted with one or more halogen and/or (1-4C)alkyl;

each R1 is independently selected from H, halogen, (1-4C)alkyl and (1-4C)alkoxy;

R2 is H, (1-4C)alkyl, or (1-6C) alkenyl, both optionally substituted with an (6-10C)aryl group, which is optionally substituted with one or more halogen and/or (1-4C)alkyl; and

R3 is H or (1-4C)alkyl, optionally substituted with one or more halogen; and

R4 is cyclopropyl or cyclopropenyl both optionally substituted with one or more halogen and/or (1-4C)alkyl; or

R2 together with R3 forms a 3-, 4-, 5- or 6-membered carbocyclic ring; and

R4 is cyclopropyl or cyclopropenyl both optionally substituted with one or more halogen and/or (1-4C)alkyl); or

R2 is H or (1-4C)alkyl; and

R3 together with R4 forms a 5-, 6- or 7-membered saturated or unsaturated carbocyclic ring;

R5 is H or (1-4C)alkyl;

or a pharmaceutically acceptable salt ~~and/or hydrate form and/or prodrug~~ thereof.

2. (Currently Amended) A compound according to claim 1, wherein A1-A5 are C, substituted with R1, or N, provided that at least one and not more than three of A1-A5 are N.
3. (Currently Amended) A compound according to claim 1, wherein one or two of A1, A2 and A5 are N, and the others are C, substituted with R1, and A3 and A4 together represent a fused benzo ring or a fused five- or six-membered nitrogen-containing aromatic ring, both optionally substituted with halogen and/or (1-4C)alkyl.
4. (Currently Amended) A compound according to claim 1, wherein
R2 is H, (1-4C)alkyl or (1-6C)alkenyl, both optionally substituted with an (6-10C)aryl group, which is optionally substituted with one or more halogen and/or (1-4C)alkyl; and
R3 is H or (1-4C)alkyl, optionally substituted with one or more halogen; and
R4 is cyclopropyl or cyclopropenyl, both optionally substituted with one or more halogen and/or (1-4C)alkyl.
5. (Previously Presented) A compound according to claim 1, wherein
R2 together with R3 forms a 3-, 4-, 5- or 6-membered carbocyclic ring; and

- R4 is cyclopropyl or cyclopropenyl, both optionally substituted with one or more halogen and/or (1-4C)alkyl.
6. (Previously Presented) A compound according to claim 1, wherein
R2 is H or (1-4C)alkyl; and
R3 together with R4 forms a 5-, 6- or 7-membered saturated or unsaturated carbocyclic ring.
7. (Previously Presented) A compound according to claim 2, wherein
R2 is H, (1-4C)alkyl or (1-6C)alkenyl, both optionally substituted with an (6-10C)aryl group, which is optionally substituted with one or more halogen and/or (1-4C)alkyl; and
R3 is H or (1-4C)alkyl optionally substituted with one or more halogen; and
R4 is cyclopropyl or cyclopropenyl both optionally substituted with one or more halogen and/or (1-4C)alkyl.
8. (Previously Presented) A compound according to claim 2, wherein
R2 together with R3 forms a 3-, 4-, 5- or 6-membered carbocyclic ring; and
R4 is cyclopropyl or cyclopropenyl, both optionally substituted with one or more halogen and/or (1-4C)alkyl.
9. (Previously Presented) A compound according to claim 2, wherein
R2 is H or (1-4C)alkyl; and
R3 together with R4 forms a 5-, 6- or 7-membered saturated or unsaturated carbocyclic ring.
10. (Previously Presented) A compound according to claim 3, wherein
R2 is H, (1-4C)alkyl or (1-6C)alkenyl, both optionally substituted with an

(6-10C)aryl group which is optionally substituted with one or more halogen and/or (1-4C)alkyl; and

R3 is H or (1-4C)alkyl optionally substituted with one or more halogen; and

R4 is cyclopropyl or cyclopropenyl both optionally substituted with one or more halogen and/or (1-4C)alkyl.

11. (Previously Presented) A compound according to claim 3, wherein
R2 together with R3 forms a 3-, 4-, 5- or 6-membered carbocyclic ring; and
R4 is cyclopropyl or cyclopropenyl, both optionally substituted with one or more halogen and/or (1-4C)alkyl.
12. (Previously Presented) A compound according to claim 3,
wherein
R2 is H or (1-4C)alkyl; and
R3 together with R4 forms a 5-, 6- or 7-membered saturated or unsaturated carbocyclic ring.
13. (Previously Presented) A compound according to claim 1, wherein X is O.
14. (Previously Presented) A compound according to claim 4, wherein R4 is cyclopropyl.
15. (Previously Presented) A compound according to claim 5, wherein R4 is cyclopropyl.
16. (Previously Presented) A compound according to claim 2, wherein A1, A3, A4 and A5 are C, substituted with R1, and A2 is N.
17. (Cancelled)
18. (Previously Presented) A compound according to claim 13, wherein

A1, A3, A4 and A5 are C, substituted with R1, and A2 is N;
R2 is H, (1-4C)alkyl or (1-4C)alkenyl; and
R3 is H or (1-4C)alkyl, optionally substituted with one or more halogen; and
R4 is cyclopropyl; or
R2 together with R3 forms a 3-, 4-, 5- or 6-membered carbocyclic ring; and
R4 is cyclopropyl.

19. (Cancelled)

20. (Previously Presented) A compound according to claim 13, wherein

A1, A3, A4 and A5 are C;
A2 is N;
R1 is H
R2 is ethenyl;
R3 is H;
R4 is cyclopropyl; and
R5 is H.


21. (Cancelled)

22. (Currently Amended) A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

23. (Cancelled)

24. (Cancelled)

25. (Cancelled)
26. (Cancelled)
27. (Cancelled).
28. (Cancelled)
29. (Currently Amended) A method of contraception comprising administering a pharmaceutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof to a subject in need thereof.
30. (Currently Amended) A method of treating a gynaecological disorder selected from the group consisting of endometriosis, dysmenorrhea, dysfunctional uterine bleeding and severe premenstrual syndrome, the method comprising administering a pharmaceutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof to a subject in need thereof.
31. (Currently Amended) A method of hormone replacement therapy comprising administering a pharmaceutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof to a subject in need thereof.
32. (New) A compound according to claim 4, wherein R2 is H, (1-4C)alkyl or (1-4C)alkenyl.
33. (New) A compound of the formula



34. (New) The method according to claim 30, wherein the gynaecological disorder is endometriosis.
35. (New) A method of treating a gynaecological disorder selected from the group consisting of endometriosis, dysmenorrhea, dysfunctional uterine bleeding and severe premenstrual syndrome, the method comprising administering the compound according to claim 33 or a pharmaceutically acceptable salt thereof to a subject in need thereof.
36. (New) The method according to claim 35, wherein the gynaecological disorder is endometriosis.
37. (New) A pharmaceutical composition comprising a compound according to claim 33 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.